MARKET

INMB

INMB

Inmune Bio Inc
NASDAQ
1.910
-0.100
-4.98%
After Hours: 1.910 0 0.00% 16:10 12/15 EST
OPEN
2.020
PREV CLOSE
2.010
HIGH
2.020
LOW
1.860
VOLUME
414.05K
TURNOVER
--
52 WEEK HIGH
11.64
52 WEEK LOW
1.380
MARKET CAP
50.78M
P/E (TTM)
-0.8923
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at INMB last week (1208-1212)?
Weekly Report · 20h ago
INmune Bio Terminates $75M At-the-Market Sales Agreement With RBC Capital Markets And BTIG, Effective December 19, 2025; Prior To Termination, The Co Issued And Sold 1,353,469 Shares Of Common Stock Under The Sales Agreement, Raising Net Proceeds Of ~$10.5M
Benzinga · 5d ago
Inmune Bio Ends Sales Agreement with RBC and BTIG
TipRanks · 5d ago
INMUNE BIO INC - COMPANY TERMINATES SALES AGREEMENT EFFECTIVE DECEMBER 19, 2025 - SEC FILING
Reuters · 5d ago
INMUNE BIO INC - AMENDMENT EXTENDS EXPIRATION DATE OF RIGHTS AGREEMENT TO DECEMBER 31, 2026 - SEC FILING
Reuters · 12/08 21:02
Weekly Report: what happened at INMB last week (1201-1205)?
Weekly Report · 12/08 09:55
Inmune Bio Unveils Promising Alzheimer’s Trial Data
TipRanks · 12/05 21:43
INmune Bio Reports Phase 2 Trial Data Showing XPro1595 Slows Neurodegeneration in Early Alzheimer’s Disease
Reuters · 12/05 21:01
More
About INMB
INmune Bio Inc. is a clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. The Company has three product platforms. The Dominant-Negative Tumor Necrosis Factor (DN-TNF) product platform utilizes dominant-negative technology to selectively neutralize soluble TNF. DN-TNF product candidates are in clinical trials to determine if they can treat Mild Alzheimer’s disease, Mild Cognitive Impairment and treatment-resistant depression (XPro). The Natural Killer Cell Priming Platform includes INKmune, developed to prime a patient’s NK cells to eliminate minimal residual disease in patients with cancer and is in trials in metastatic castration-resistance prostate cancer. The third program, CORDStrom, is a proprietary pooled, allogeneic, human umbilical cord-derived mesenchymal Stromal/Stem cell (hucMSCs) platform that has completed a trial in recessive dystrophic epidermolysis bullosa.

Webull offers INmune Bio Inc stock information, including NASDAQ: INMB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, INMB stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading INMB stock methods without spending real money on the virtual paper trading platform.